Evidence on the low probability of FISH positivity in a low-grade tumor is strong enough to convince some researchers that HER2 assessment may be considered unnecessary in a subgroup of low-grade tumors (10, 19, 29). The gene discussed is ERBB2; the disease is neoplasm.